{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with atypical teratoid rhabdoid tumor.","id":"OG000","title":"Cohort 12"}],"populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug. No participants had an objective response in this cohort.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"DOR as Determined by the Investigator Using RANO Criteria in Participants With ATRT","type":"SECONDARY"}